

## **Product datasheet for TR304788**

## Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com

**OriGene Technologies, Inc.** 9620 Medical Center Drive, Ste 200

EU: info-de@origene.com CN: techsupport@origene.cn

## **ELOVL4 Human shRNA Plasmid Kit (Locus ID 6785)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** ELOVL4 Human shRNA Plasmid Kit (Locus ID 6785)

**Locus ID:** 6785

Synonyms: ADMD; CT118; ISQMR; SCA34; STGD2; STGD3

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Selection:

Puromycin

Format: Retroviral plasmids

Components: ELOVL4 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

6785). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 022726, NM 022726.1, NM 022726.2, NM 022726.3, BC038506, BC038506.1,

NM 022726.4

UniProt ID: O9GZR5


Summary: This gene encodes a membrane-bound protein which is a member of the ELO family,

proteins which participate in the biosynthesis of fatty acids. Consistent with the expression of the encoded protein in photoreceptor cells of the retina, mutations and small deletions in this gene are associated with Stargardt-like macular dystrophy (STGD3) and autosomal dominant Stargardt-like macular dystrophy (ADMD), also referred to as autosomal dominant

atrophic macular degeneration. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).